PLANO, Texas--(BUSINESS WIRE)--Secretome Therapeutics today announced the launch of a Phase 1, dose-escalating trial of STM-01, Secretome’s neonatal cardiac progenitor cell (nCPC) product, for the ...
Hosted on MSN
Sutro Biopharma’s promising phase 1 study on STRO-004: A potential game-changer in cancer treatment
Sutro Biopharma (STRO) announced an update on their ongoing clinical study. Study Overview: Sutro Biopharma is conducting a Phase 1 open-label study titled A Phase 1 Open-Label Study to Evaluate ...
The Phase 1 clinical trial, STRIKE-001 (NCT07103018), is a multi-center, open-label dose escalation of KTX-2001 monotherapy (Part A) and in combination with darolutamide, an oral, nonsteroidal ...
Pfizer Inc (PFE) announced an update on their ongoing clinical study. Pfizer Inc. has launched a Phase 1 clinical study titled A Phase 1, Randomized, Multi-Center, Double-Blind, Sponsor Open, ...
Phase 1 data demonstrates durable responses and rPFS coupled with a manageable safety profile rPFS of 7.9-8.9 months in heavily pre-treated mCRPC patients Preliminary results are encouraging with deep ...
Cohort 4 data demonstrated positive safety and efficacy results, including additional clinical benefit observed following longer 8-week treatment 75% of soquelitinib patients achieved EASI 75, 25% ...
Corbus Pharmaceuticals initiates combination cohort of CRB-701 study for solid tumors, focusing on HNSCC and cervical cancer. Data update expected this year. Corbus Pharmaceuticals Holdings, Inc.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results